QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress targets inhalant abuse by banning high-concentration dusters

S. 5002 — Duster Inhalation Prevention Act · Filed by Ron Wyden (D-OR) · 1 cosponsor · Introduced Jul 15, 2026 · Referred to committee

82%
Transparency
Typical bill: 82%
8/100
Hidden-provision risk
Typical bill: 15/100
Public Health Inhalant Abuse Prevention

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill directs the Consumer Product Safety Commission to classify certain refrigerant gases (HFC-152a and HFC-134a) used in compressed air dusters as hazardous substances and ban duster products containing more than 18 mg of these chemicals. The bill aims to prevent inhalant abuse by making dusters harder to obtain for that purpose, while exempting FDA-regulated drugs and allowing the CPSC to add other harmful propellants to the ban list.

Why we flagged it

The bill's operative mechanism—banning high-concentration duster products and empowering the CPSC to regulate propellants—directly addresses inhalant abuse as a public-health problem. The 18 mg threshold and stockpile-prevention language are technical safeguards, not hidden riders.

What the text implies

  • The 18 mg threshold may effectively eliminate most commercial duster products currently on the market, potentially disrupting the cleaning-supply industry's existing product lines and forcing reformulation or substitution with alternative propellants.
  • The stockpile prohibition (capping manufacture/import at 105% of base-period volume) may create supply-chain bottlenecks if demand for compliant dusters exceeds the cap, potentially raising prices for legitimate users.

The full analysis lists 3 implications of this text.

Who stands to gain

manufacturers of alternative propellant technologies (e.g., hydrofluoroolefins, hydrofluoropolyether; pharmaceutical and medical-device companies (exempted from the ban, may see increased demand for FDA; consumer-safety advocacy organizations (may receive funding or support for enforcement/monitoring)

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record